NCT01485588 - Safety and Tolerability Study for Age-Related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG

hI-con1™ 60µl

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

DRUG

hI-con1™ 150µl

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

DRUG

hI-con1™ 300µl

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

Trial Locations (5)

Palmetto Retina Center, West Columbia

Rocky Mountain Eye Center, P.C., Missoula

Valley Retina Institute, PA, McAllen

Retina Research Center, Austin

Retina & Vitreous Center of Southern Oregon, P.C., Ashland